Gilead
- Alpha BioPharma Advisers, in partnership with PropThink, have undertaken a meticulous evaluation of Gilead Sciences (GILD), tackling the ongoing debate surrounding Sovaldi and Gilead’s longterm … Continue Reading
Read nowSearch Results for gene therapy
There’s Reason to Believe Tekmira Can Overcome this Safety Issue
Insights - There may be reason for investors to get comfortable with Tekmira's (TKMR) latest safety issue. Here's why.
Read now
Ohr Calls Drug Analysis ‘Positive’ but Misses Primary Goal
Insights - Ohr Pharmaceutical (OHRP) on Tuesday released interim results from a phase 2 study of its Squalamine eye drops in Wet Age-related Macular Degeneration (AMD). Squalamine eye drops, … Continue Reading
Read now
Antibiotic Incentives Loom, Cubist Still Positioned to Benefit
Research - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read now
Sarepta: Big Plans for the Second Half
Research - Sarepta (SRPT) will file a NDA and get 5 new trials off the ground in the next 7 months.
Read nowA Roundup our Top Stories from the Week
Insights - PropThink published an ASCO 2014 preview early this week, highlighting events that will capture Wall Street’s interest as abstracts are published online and presentations kick off at … Continue Reading
Read now
ASCO 2014 Preview and One Micro-Cap of Interest
Research - The American Society of Clinical Oncology (ASCO) annual meeting is right around the corner, and healthcare investors will have a close eye on ASCO for … Continue Reading
Read now